Healthcare

Dimerix Begins Phase 3 Recruitment for Kidney Disease Study in Mexic...

Dimerix Limited (ASX:DXB) has announced the commencement of patient recruitment for its ‘ACTION3’ Phase 3 clinical trial. This significant milestone i...

Pro Medicus Limited (ASX: PME): Why the Surge in Share Price?

The Pro Medicus Limited,(ASX: PME),share price has experienced a remarkable 63.6% increase since the beginning of 2024. This impressive rise in value...

Noxopharm Obtains $1.8 Million in Funding Ahead of R&D Rebate

Noxopharm Ltd,(ASX:NOX),has secured $1.8 million in advanced funding through a secured loan agreement with Endpoints Capital Pty Ltd, a specialist in...

CSL Ltd and Pro Medicus Limited: Current Performance and Key Insight...

As the year progresses, CSL Ltd and Pro Medicus Limited are making significant strides in their respective sectors. CSL Ltd, an,ASX healthcare stock,,...

Exploring the Latest Developments in RMD Shares

ResMed CDI has been on a remarkable upward trajectory in 2024, with its share price surging 42.6% since the start of the year. Investors are taking a...

Breakthroughs in Coronary Disease Indicate Potential Future Reductio...

Coronary disease remains the leading cause of death in Australia, accounting for about 24% of all fatalities. While the World Health Organisation esti...

Orthocell Products Enter Canadian Market with Initial Sale via Partn...

Orthocell Ltd,(ASX: OCC,), has advanced its global market expansion by making its debut in the Canadian biotech sector with the first sale of its prod...

Immuron Receives Positive Feedback from US FDA Ahead of IMM-529 Inve...

Immuron Ltd,(ASX:IMC),has received positive feedback from the United States Food and Drug Administration (FDA) regarding its IMM-529 product, aimed at...

Biotron Ltd (ASX:BIT) Faces Backlash Over Disappointing COVID Drug T...

Biotron Ltd,(ASX:BIT),is under scrutiny following the results of its latest trial for its COVID-19 drug, BIT225-012. The trial results, which were eag...

Pacific Smiles CEO Andrew Vidler Steps Down Amid Company Transition

Pacific Smiles Group Ltd,(ASX:PSQ),, a prominent player in the dental industry, has announced the resignation of its Chief Executive Officer, Andrew V...

Orthocell Expands Global Reach with Collagen-Based Dental Bone Repai...

Orthocell (ASX:OCC) has achieved another milestone with its collagen-based bone repair product, Striate+, as the company confirms initial sales in Can...

CLEO Diagnostics Launches Major Ovarian Cancer Blood Test Trials in...

CLEO Diagnostics (ASX:COV) has embarked on significant U.S.-based trials aimed at assessing the reliability and effectiveness of its ovarian cancer-de...

Race Oncology Finalizes Board Overhaul to Advance Next Growth Phase

Race Oncology Ltd,(ASX: RAC),has reached a significant milestone in its strategic development, completing a comprehensive board renewal process aimed...

Lumos Diagnostics Adds Tenmile Ventures as New Shareholder

Lumos Diagnostics Holdings Ltd,(ASX:LDX),is raising A$10 million through a pro rata accelerated non-renounceable entitlement offer, with the retail co...

The Transformative Impact of Regenerative Medicine on Healthcare

Regenerative medicine is revolutionizing health care by focusing on repairing, replacing, or regenerating damaged or diseased cells, tissues, or organ...

Lumos Diagnostics Gains Twiggy Forrest as Key Investor in $10M Raise

Emerging companies Lumos Diagnostics, Memphasys, and Vitura Health are making notable strides in their respective sectors. From advancing diagnostic t...

Lumos Diagnostics Wins Twiggy Forrest as Major Investor

In today's market updates, Lumos Diagnostics aims to raise $10 million to advance its diagnostic technology, while,ASX healthcare stock,Memphasys vent...

Noxopharm Targets Challenging Brain Cancer with New Developments

This week, several,ASX-listed healthcare stocks,made headlines with notable updates. Noxopharm Ltd achieved promising results in glioblastoma treatmen...

CSL Ltd: A Closer Look at the Biotechnology Leader

Since the start of 2024, CSL Ltd,(ASX: CSL),has seen its share price rise by 6.0%. This growth has sparked significant interest among investors. Here’...

Emyria (ASX:EMD) Sees 10% Surge on Promising Interim Results for MDM...

On Monday, shares of Emyria (ASX:EMD) experienced a notable 9.4% increase, reaching 3.5 cents per share, following the announcement of positive interi...